Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

Suggested remit: To appraise the clinical and cost effectiveness of sebetralstat within its marketing authorisation for treating acute attacks of hereditary angioedema.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6284

Provisional Schedule

Committee meeting: 1:

14 October 2025

Expected publication:

17 December 2025

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors

KalVista (sebetralstat)

 

British Society for Allergy & Clinical Immunology

 

BSI Clinical Immunology Professional Network (BSI-CIPN)

 

Royal College of Pathologists

 

Royal College of Physicians

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

HAE UK

Associated public health groups

None

Comparator companies

Takeda (cinryze, icatibant) (confidentiality agreement signed, participating)

 

Accord (icatibant) (confidentiality agreement not signed, not participating)

 

Celix Pharma (icatibant) (confidentiality agreement not signed, not participating)

 

Cipla (icatibant) (confidentiality agreement not signed, not participating)

 

CSL Behring (Berinert) (confidentiality agreement not signed, not participating)

 

Ethypharm (icatibant) (confidentiality agreement not signed, not participating)

 

Glenmark Pharmaceutical (icatibant) (confidentiality agreement not signed, not participating)

 

Martindale Pharmaceuticals (icatibant) (confidentiality agreement not signed, not participating)

 

Pharming Group N.V (ruconest) (confidentiality agreement not signed, not participating)

 

Piramal Critical Care (icatibant) (confidentiality agreement not signed, not participating)

 

Sandoz (icatibant) (confidentiality agreement not signed, not participating)

 

Wockhardt (icatibant) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

None

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual